DalsnaFinance

Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia

Markets PR Newswire By PR Newswire 11 Jun 2026 18:00 1 min read
Blood Cancer United Acquires Investigational Drug Supply to Preserve Access for Children with Rare, Fatal Leukemia

First-of-its-kind nonprofit intervention enables continued compassionate use of a promising treatment for children facing a 15% to 30% survival rate WASHINGTON, June 11, 2026 /PRNewswire/ -- In an unprecedented intervention, Blood Cancer United announced that it has acquired the remaining...

First-of-its-kind nonprofit intervention enables continued compassionate use of a promising treatment for children facing a 15% to 30% survival rate WASHINGTON, June 11, 2026 /PRNewswire/ -- In an unprecedented intervention, Blood Cancer United announced that it has acquired the remaining...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.